Literature DB >> 33313065

Spectrums and Prognosis of Kidney Disease in Patients with Ankylosing Spondylitis.

Dafeng He1,2, Rong Wang1,2, Shaoshan Liang1, Dandan Liang1, Feng Xu1, Caihong Zeng1, Zheng Tang1,3.   

Abstract

BACKGROUND/AIMS: Renal involvement was a common extra-articular manifestation of ankylosing spondylitis (AS). Few reports have investigated the pathological characteristics and renal outcomes of AS patients with kidney disease. The aim of this study was to investigate the pathological spectrums and the renal prognosis of AS patients with kidney disease.
METHODS: This retrospective and observational study was conducted working on 62 patients (47 males and 15 females) with a diagnosis of AS (ACR, 1984) and renal biopsies between 2008 and 2017. The histopathological findings and associated clinical manifestations were collected, and the renal prognoses of patients with kidney disease were evaluated too. Multivariate binary logistic regression analysis was performed to identify risk factors for the occurrence of IgA nephropathy (IgAN).
RESULTS: Renal biopsy revealed that IgAN accounted for a majority (74.2%) of the kidney disease with AS, while membranous nephropathies, minimal change disease, focal segmental glomerulosclerosis, and other lesions accounted for a small minority. Multivariate analysis revealed that serum immunoglobulin A >3.45 g/L and immunoglobulin G >9.06 g/L were risk factors for the occurrence of IgAN. With a median follow-up time of 24.3 months, 28 patients (50.9%) reached complete remission, 9 patients (16.4%) had partial remission, and 1 patient had an eGFR decline >30%. No difference was found in prognosis between IgAN and non-IgAN.
CONCLUSION: IgAN occurred in 76.4% of the kidney disease with AS, and higher serum immunoglobulin A and G increased the risk for the occurrence of IgAN. The renal prognosis of kidney disease in AS was good.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Ankylosing spondylitis; IgA nephropathy; Kidney; Pathological spectrums; Prognosis

Year:  2020        PMID: 33313065      PMCID: PMC7706489          DOI: 10.1159/000509248

Source DB:  PubMed          Journal:  Kidney Dis (Basel)        ISSN: 2296-9357


  31 in total

1.  Infliximab in a patient with ankylosing spondylitis and secondary IgA nephropathy requiring haemodialysis.

Authors:  Elisa Marocchi; Antonio Spadaro; Konstantinos Giannakakis; Roberta Priori; Guido Valesini
Journal:  Clin Exp Rheumatol       Date:  2010-06-24       Impact factor: 4.473

2.  IgA nephropathy in patients with spondyloarthritis followed-up at the Rheumatology Service of Hospital das Clínicas/UFMG.

Authors:  Daniela Castelo Azevedo; Gilda Aparecida Ferreira; Marco Antônio P Carvalho
Journal:  Rev Bras Reumatol       Date:  2011 Sep-Oct

3.  Diffuse alveolar hemorrhage in a patient with ankylosing spondylitis.

Authors:  Shintaro Hara; Noriho Sakamoto; Yuji Ishimatsu; Tomoyuki Kakugawa; Midori Shimada; Shigeru Kohno
Journal:  Intern Med       Date:  2013       Impact factor: 1.271

4.  Renal amyloidosis in ankylosing spondylitis: A monocentric study and review of literature.

Authors:  Samia Barbouch; Meriam Hajji; Fatima Jaziri; Raja Aoudia; Eya Fellah; Hafedh Hedri; Rym Goucha; Fethi Ben Hamida; Fethi Ben Taarit; Imen Gorsane; Taieb Ben Abdallah
Journal:  Saudi J Kidney Dis Transpl       Date:  2018 Mar-Apr

5.  A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients.

Authors:  Cai-Hong Zeng; Weibo Le; Zhaohui Ni; Minfang Zhang; Lining Miao; Ping Luo; Rong Wang; Zhimei Lv; Jianghua Chen; Jiong Tian; Nan Chen; Xiaoxia Pan; Ping Fu; Zhangxue Hu; Lining Wang; Qiuling Fan; Hongguang Zheng; Dewei Zhang; Yaping Wang; Yanhong Huo; Hongli Lin; Shuni Chen; Shiren Sun; Yanxia Wang; Zhangsuo Liu; Dong Liu; Lu Ma; Tao Pan; Aiping Zhang; Xiaoyu Jiang; Changying Xing; Bing Sun; Qiaoling Zhou; Wenbing Tang; Fuyou Liu; Yinghong Liu; Shaoshan Liang; Feng Xu; Qian Huang; Hongbing Shen; Jianming Wang; Yu Shyr; Sharon Phillips; Stéphan Troyanov; Stéphan Trojanov; Agnes Fogo; Zhi-Hong Liu
Journal:  Am J Kidney Dis       Date:  2012-07-20       Impact factor: 8.860

6.  IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.

Authors:  Hitoshi Suzuki; Junichi Yasutake; Yuko Makita; Yuki Tanbo; Kohei Yamasaki; Tadashi Sofue; Toshiki Kano; Yusuke Suzuki
Journal:  Kidney Int       Date:  2018-01-10       Impact factor: 10.612

7.  [Renal involvement in ankylosing spondylitis: concerning 210 cases].

Authors:  C Ben Taarit; H Ajlani; F Ben Moussa; T Ben Abdallah; H Ben Maïz; A Khedher
Journal:  Rev Med Interne       Date:  2005-09-30       Impact factor: 0.728

8.  Comparison of secondary IgA nephropathy in patients with ankylosing spondylitis and rheumatoid arthritis.

Authors:  Dafeng He; Rong Wang; Shaoshan Liang; Dandan Liang; Feng Xu; Caihong Zeng; Zheng Tang
Journal:  Mod Rheumatol       Date:  2019-11-22       Impact factor: 3.023

9.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

10.  Higher Levels of Secretory IgA Are Associated with Low Disease Activity Index in Patients with Reactive Arthritis and Undifferentiated Spondyloarthritis.

Authors:  Fabián Salas-Cuestas; Wilson Bautista-Molano; Juan M Bello-Gualtero; Ivonne Arias; Diana Marcela Castillo; Lorena Chila-Moreno; Rafael Valle-Oñate; Daniel Herrera; Consuelo Romero-Sánchez
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.